Study Comparing Olanzapine With Haloperidol for the Relief of Nausea and Vomiting in Patients With Advanced Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-05-31

Study Completion Date

2008-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the efficacy and safety of Haldol (haloperidol) and olanzapine in the control of chronic nausea with advanced cancer patients who have failed first line antiemetic therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer

NCT05403580

Advanced Malignant Solid Neoplasm Hematopoietic and Lymphoid Cell Neoplasm

WITHDRAWN PHASE3

Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients

NCT03137121

Advanced Cancer

COMPLETED PHASE2/PHASE3

Feasibility of Olanzapine at REduced doSe in hIGHly Emetogenic chemoTherapy

NCT04075955

Chemotherapy-induced Nausea and Vomiting

COMPLETED PHASE3

Individualised Versus Standard Care for Breast Cancer Patients at High-risk for Chemotherapy-induced Nausea and Vomiting The ILIAD Study

NCT02861859

Breast Cancer

COMPLETED PHASE3

Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients

NCT04939090

Advanced Malignant Solid Neoplasm Anorexia Hematopoietic and Lymphoid Cell Neoplasm

RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to compare the efficacy and safety of haloperidol and olanzapine in the control of chronic nausea with advanced cancer patients who have failed first line antiemetic therapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nausea Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Olanzapine

Intervention Type DRUG

Haldol

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \>18 years of age
* Significant nausea/vomiting
* Failed maxeran and domperidone
* Underlying treatment of causes has failed
* Adequate cognitive function
* Communicates well

Exclusion Criteria

* Partial/complete bowel obstruction
* Currently taking Haldol or olanzapine
* Has drug induced extrapyramidal symptoms
* Parkinson's disease
* Undergoing chemotherapy or radiotherapy (RT) to brain, abdomen, stomach or esophagus

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No